GLP1R and type 2 diabetes mellitus: A large real world evidence demonstrated that when comparing several GLP-1 receptor agonists versus DPP-4 inhibitors treatments in patients with a baseline cardiovascular risk, the incidence of adverse events was much lower for the former [8]; the GLP-1 semaglutide reduced the risk of major adverse cardiovascular events vs comparators in a broad T2DM population [9].